SAN FRANCISCO, California (August 12, 2025) — Grove AI, a company advancing the next generation of clinical trials with artificial intelligence, today announced the formation of its Clinical Research Site Advisory Council, a group of distinguished doctors, operational leaders, executives, and technical experts drawn from across the clinical research ecosystem. Members include leaders from academic medical centers, integrated research organizations, standalone research sites, and global contract research organizations who will help shape how clinical trials are designed and delivered with Grove AI.

The council includes Dr. Mark Weinberger, President and CEO, The IMA Group; Tyler Hastings, Managing Partner, DelRicht Research; Andrea Basaraba, Chief Operating Officer, Redbird Research; Dr. Jack Zeng, Director of IT Applications, Stanford Department of Medicine; Dr. Michelle Papka, Scientific Director and Founder, The Cognitive & Research Center of New Jersey; and Phil Bach, Executive Vice President of Global Clinical Research, Celerion.

Together, these leaders bring decades of experience running leading Phase I to III clinical trials across diverse therapeutic areas, including cardiometabolic, neurology, psychiatry, dermatology, gastroenterology, and more. Their collective expertise spans clinical trial operations, patient recruitment and retention, regulatory compliance, technology integration, and large-scale, end-to-end trial execution, creating a uniquely comprehensive perspective on the challenges and opportunities facing modern clinical research.

By integrating the multidisciplinary expertise of this group, Grove AI will advance a more efficient, inclusive, and patient-centered research ecosystem. Together, the council and Grove AI will help research teams navigate the growing complexity of modern trials, deliver better outcomes for patients, and enable the life sciences industry to bring new treatments to market faster.